Vascular complications of diabetes mellitus: What role for phospholipid-binding antibodies?

Lupus

Volumn 7, Issue 7, 1998, Pages 469-474

  Galtier Dereure, F ^a   Biron, C ^a,b   Vies, M ^a   Bourgeois, V ^a   Schved, J F ^a   Bringer, J ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Anticardiolipin antibodies; Diabetes mellitus; Lupus anticoagulant; Vascular complications

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID BINDING PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; VASCULAR DISEASE;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; CROSS-SECTIONAL STUDIES; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0031672027     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920488     Document Type: Article

References (42)

1. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
2. Exner T. Comparison of test methods for the lupus anticoagulant: International survey on lupus anticoagulants-I (ISLA-1) Thromb Haemost 1990; 64: 478-484.
3. Galli M et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7154
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation' β2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
5. Love PE, Santoro SA. Antiphospholipid antibodies anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance Ann Intern Med 12990; 112: 682-698
6. Rote NS, Dostal-Johnson D, Branch DW Antiphospholipid antibodies and recurrent pregnancy loss correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol 1990; 63: 575-584.
7. Balasch J et al. Antiphospholipid antibodies in unselected patients with repeated abortion Hum Reprod 1990; 5: 43-46.
8. Harris EN. The antiphospholipid syndrome - an introduction In Harris EN, Exner T, Asherson RA (eds) Phospholipid-binding antibodies. CRC Press, Boca Raton, Florida, 1991, pp 373-386
9. Baker WF, Brick RL. Antiphospholipid antibodies in coronary heart disease a review Semin Thromb Hemost 1994; 20: 27-45
10. Ginsberg JS et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
11. Hendra TJ et al. Anticardiolipin antibody level in diabetic subjects with and without coronary artery disease. Postgrad Med J 1989; 65: 140-143
12. Lorini R et al. Anticardiolipin antibodies in children and adolescents with insulin-dependent diabetes mellitus. Eur J Pediatr 1995; 154: 105-108.
13. Triolo G et al. Detection of antiphospholipid (cardiohpin, phosphatidylserine) antibodies in the serum of patients with non insulin-dependent (type 2) diabetes mellitus and macroangiopathy. Coexistence of anti-platelet reactivity. Diabetes Res 1989; 10: 63-67.
14. World Health Organization. Diabetes mellitus report of a WHO study group (1985) Technical report series 727 World Health Organization Geneva
15. Brandt JT et al. Criteria for the diagnosis of lupus anticoagulant' an update. On behalf of the Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardization Committee of the ISTH Thromb Haemost 1975; 74: 1185-1190.
16. Anzai Ket al. Production of anti-cardiolipin antibody in AKR/J mice with streptozocin-induced msulitis and diabetes. Diabetes Res Clin Proct 1993; 20: 29-37.
17. Quereda C et al. Prevalence of antiphospholipid antibodies in nephropathies not due to systemic lupus erythematosus Am J Kidney 1994; 23: 555-561.
18. Sitter Y, Spannagl M, Schiffl H. Anticardiolipin antibodies and lupus anticoagulant activity in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus. Ann Haematol 1992; 65: 79-82
19. Garcia-Martin F Met al Anticardiolipin antibodies and lupus anticoagulant activity in end-stage renal disease, Nephrol Dial Transplant 1991; 6: 543-547.
20. Grönhagen-Riska C et al. Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. Br Med J 1990; 300: 1996-1997.
21. Hughson MD et al. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome Am J Kidney Dis 1992; 20: 150-158
22. Farrugia E et al. Lupus anticoagulant in systemic lupus erythematosus a clinical and pathological study Am J Kidney Dis 1992; 20: 463-471
23. Kon SP, Kwan JT, Raftery MJ Reversible renal failure due to the antiphospholipid antibodies syndrome, pre-eclampsia and renal thrombotic microangiopathy Clin Nephrol 1995; 44: 271-273
24. Amigo MC et al. Renal involvement in primary antiphospholipid syndrome J Rheumatol 1992; 19: 1181-1185.
25. Domrongkitchaiporn S et al. Renal microangiopathy in the primary antiphospholipid syndrome: a case report with literature review Nephron 1994; 68: 128-132.
26. Deckert T et al. Albummuria reflects widespread damage The Steno hypothesis Diabetologia 1989; 32: 219-226
27. Knobl P et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non insulin-dependant) diabetic patients Diabetologia 1993; 36: 1045-1050.
28. Kario K et al Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patient with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-1120.
29. Leurs PB, Van Oerle R, Wolffenbuttel BH, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost 1997; 77: 472-476
30. Hamsten A et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113-119
31. Morton KE M et al. Coronary artery bypass graft failure - an autoimmune phenomenon Lancet 1986; ii: 1353-1356.
32. Kattwinkel N et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Int Med 1992; 116: 974-976
33. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' antibodies. Blood 1994; 84: 2854-2867.
34. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome' a possible mechanism for thrombosis. Am J Obstet Gynecol 1993; 168: 206-210.
35. Cariou R, Tobelem G, Bellucci S. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells-Inhibition of thrombo-modulin-dependent protein C activation Thromb Haemost 1988; 60: 54-58.
36. Triplett DA Antiphospholipid antibodies: proposed mechanisms of action. Ant J Reprod Immunol 1992; 28: 211-215
37. Hasselaar P et al. Synergistic effect of low doses of tumour necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost 1989; 62: 654-660.
38. Knobl P et al. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients Thromb Haemost 1994; 71: 692-697
39. Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes-1992, 41 S2: 32-35.
40. O'Donnell MJ et al. Platelet behaviour and haemostatic variables in type 1 (insulin-dependent) diabetic patients with and without albummuria. Diabei Med 1991; 8: 624-628.
41. Cenello A. Coagulation activation in diabetes melhtus the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125.
42. Feener EP, King CL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350: S19-S113.